Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer (ENgAGE-HK)

Bayer

Status: Completed

Conditions: Gastrointestinal Cancer

Treatments: Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

Study type: Observational

Funder types: Industry

Identifiers

NCT04081831

20319

Details and patient eligibility

About

In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer. The researchers were interested in the effect by duration of aspirin use and the effect on the time since aspirin intake has been stopped in preventing stomach, colorectal and esophagus cancer. In addition, the study also looked into the time patients survived after being diagnosed (survival rate) with cancer and number of cancer patients who died (case fatality rate). The study was based on an electronic database managed by the Health Authority in Hong Kong containing anonymized clinical information of patients living in Hong Kong.

Enrollment: 99,999 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Received prescription of either low-dose aspirin (75-300 mg) or paracetamol monotherapy during enrolment period.

Exclusion criteria

• Received prescription of aspirin monotherapy or combination one year prior to the index date
• Recorded diagnoses of any type of cancer before the index date
• Recorded procedures of colectomy, gastrectomy prior to the index date
• Age < 40 years

Trial design

99,999 participants in 2 patient groups

New-users of Low-dose aspirin (exposed group)

Description:

New-users of low-dose aspirin is defined as patients who did not receive any prescriptions of low-dose aspirin one year prior to the index date.

Treatment:

Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

Users of Paracetamol (non-exposed group)

Description:

Users of Paracetamol is defined as patients who receive first prescription of paracetamol during the study period. Since the patients receiving low-dose aspirin are potentially less healthy compared to non-users of aspirin, patients receiving paracetamol as the control group can minimise healthy user bias.